Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04482894 · ClinicalTrials.gov registry record · Phase 2
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
A Phase 2 study of Myelodysplastic Syndromes and AML, Adult, sponsored by University of Virginia.
- Active
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT04482894 is a Phase 2 study of Myelodysplastic Syndromes and AML, Adult that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 105 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04482894, a Phase 2 study of Myelodysplastic Syndromes and AML, Adult, is active but no longer recruiting, sponsored by University of Virginia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.
Conditions Studied
Interventions
- OTHER Palliative Care Visits
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04482894
The ClinicalTrials.gov registry entry for NCT04482894 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (63% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Palliative Care Visits is the first listed.
NCT04482894 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04482894 about?
NCT04482894 is a clinical study titled "Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS". The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.
What is the current status of trial NCT04482894?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2020-08-19. Estimated completion is 2026-04-01.
What conditions does trial NCT04482894 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, AML, Adult, ALL, Adult, Leukemia, Acute.
What interventions are being tested in trial NCT04482894?
The interventions under investigation include: Palliative Care Visits (OTHER).
Who is sponsoring clinical trial NCT04482894?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04482894 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.